Citigroup
SNDX icon

Citigroup’s Syndax Pharmaceuticals SNDX Stock Holding History

Citigroup’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$475K Sell
20,332
-3,409
-14% -$74.1K ﹤0.01% 3581
2025
Q4 		$499K Buy
23,741
+12,071
+103% +$211K ﹤0.01% 3572
2025
Q3 		$180K Sell
11,670
-100,082
-90% -$1.31M ﹤0.01% 4036
2025
Q2 		$1.05M Sell
111,752
-88,898
-44% -$978K ﹤0.01% 3166
2025
Q1 		$2.46M Buy
200,650
+56,198
+39% +$793K ﹤0.01% 2518
2024
Q4 		$1.91M Buy
144,452
+83,516
+137% +$1.43M ﹤0.01% 2859
2024
Q3 		$1.17M Buy
60,936
+24,584
+68% +$508K ﹤0.01% 3136
2024
Q2 		$746K Sell
36,352
-288,577
-89% -$6.04M ﹤0.01% 3114
2024
Q1 		$7.73M Buy
324,929
+162,523
+100% +$3.62M 0.01% 1420
2023
Q4 		$3.51M Buy
162,406
+42,174
+35% +$648K ﹤0.01% 1832
2023
Q3 		$1.75M Buy
120,232
+3,520
+3% +$66.6K ﹤0.01% 2085
2023
Q2 		$2.44M Sell
116,712
-443,703
-79% -$9.24M ﹤0.01% 2021
2023
Q1 		$11.8M Buy
560,415
+294,482
+111% +$7.33M 0.01% 1081
2022
Q4 		$6.77M Sell
265,933
-265,053
-50% -$6.18M 0.01% 1325
2022
Q3 		$12.8M Buy
530,986
+67,007
+14% +$1.5M 0.01% 1018
2022
Q2 		$8.93M Buy
463,979
+439,793
+1,818% +$7.33M 0.01% 1213
2022
Q1 		$421K Sell
24,186
-105,901
-81% -$1.78M ﹤0.01% 3626
2021
Q4 		$2.85M Buy
130,087
+76,023
+141% +$1.4M ﹤0.01% 2320
2021
Q3 		$1.03M Sell
54,064
-159,296
-75% -$2.65M ﹤0.01% 3057
2021
Q2 		$3.66M Buy
213,360
+33,066
+18% +$606K ﹤0.01% 2181
2021
Q1 		$4.03M Buy
180,294
+173,310
+2,482% +$3.92M ﹤0.01% 1945
2020
Q4 		$155K Buy
6,984
+5,476
+363% +$114K ﹤0.01% 5176
2020
Q3 		$22K Sell
1,508
-44,867
-97% -$684K ﹤0.01% 6134
2020
Q2 		$687K Buy
46,375
+40,872
+743% +$623K ﹤0.01% 3932
2020
Q1 		$60K Buy
5,503
+1,362
+33% +$12.8K ﹤0.01% 5812
2019
Q4 		$36K Buy
4,141
+1,947
+89% +$14.3K ﹤0.01% 6587
2019
Q3 		$17K Sell
2,194
-3,438
-61% -$31.3K ﹤0.01% 6832
2019
Q2 		$52K Buy
5,632
+1,299
+30% +$9.47K ﹤0.01% 6438
2019
Q1 		$23K Buy
4,333
+108
+3% +$616 ﹤0.01% 6889
2018
Q4 		$19K Buy
4,225
+534
+14% +$2.93K ﹤0.01% 6906
2018
Q3 		$30K Buy
3,691
+3,191
+638% +$22.7K ﹤0.01% 6888
2018
Q2 		$4K Sell
500
-1,626
-76% -$16K ﹤0.01% 7394
2018
Q1 		$30K Buy
2,126
+1,937
+1,025% +$20.6K ﹤0.01% 6510
2017
Q4 		$2K Buy
+189
New +$1.87K ﹤0.01% 7399
2017
Q3 		– Sell
-94
Closed -$1K – 7423
2017
Q2 		$1K Sell
94
-32
-25% -$366 ﹤0.01% 7198
2017
Q1 		$2K Buy
126
+122
+3,050% +$1.27K ﹤0.01% 7011
2016
Q4 		$0 Sell
4
-380
-99% -$4.16K ﹤0.01% 7317
2016
Q3 		$6K Sell
384
-87
-18% -$1.14K ﹤0.01% 6727
2016
Q2 		$5K Buy
+471
New +$6.46K ﹤0.01% 6786

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Citigroup's SNDX Position: Q1 2026 in Review

Citigroup reduced its Syndax Pharmaceuticals (SNDX) stake by 14% in Q1 2026, selling an estimated $74.1K and leaving 20,332 shares worth $475K. The position accounts for ﹤0.01% of the portfolio, ranked #3581.

Citigroup first reported a position in SNDX in Q2 2016 and has held it in 39 quarters since. The position peaked at $12.8M in Q3 2022. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Citigroup held 20,332 shares of Syndax Pharmaceuticals worth $475K as of Q1 2026.
  • Citigroup sold 3,409 Syndax Pharmaceuticals shares in Q1 2026, an estimated $74.1K.
  • Syndax Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3581 holding.
  • Citigroup first reported a position in Syndax Pharmaceuticals in Q2 2016 and has held it in 39 quarters since.
  • Citigroup's Syndax Pharmaceuticals position peaked at $12.8M in Q3 2022.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.